

Emmanuel S Antonarakis Mbbch

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/7196464/publications.pdf>

Version: 2024-02-01

333
papers

22,563
citations

25423

59
h-index

12272

138
g-index

340
all docs

340
docs citations

340
times ranked

26616
citing authors

#	ARTICLE	IF	CITATIONS
1	Safety and preliminary immunogenicity of JNJ-64041809, a live-attenuated, double-deleted <i>Listeria monocytogenes</i> -based immunotherapy, in metastatic castration-resistant prostate cancer. <i>Prostate Cancer and Prostatic Diseases</i> , 2022, 25, 219-228.	2.0	12
2	Molecular and Clinical Characterization of Patients With Metastatic Castration Resistant Prostate Cancer Achieving Deep Responses to Bipolar Androgen Therapy. <i>Clinical Genitourinary Cancer</i> , 2022, 20, 97-101.	0.9	14
3	Association between pathogenic germline mutations in BRCA2 and ATM and tumor-infiltrating lymphocytes in primary prostate cancer. <i>Cancer Immunology, Immunotherapy</i> , 2022, 71, 943-951.	2.0	9
4	Clinical and genomic features of <i>SPOP</i> mutant prostate cancer. <i>Prostate</i> , 2022, 82, 260-268.	1.2	20
5	Definitions of disease burden across the spectrum of metastatic castration-sensitive prostate cancer: comparison by disease outcomes and genomics. <i>Prostate Cancer and Prostatic Diseases</i> , 2022, 25, 713-719.	2.0	17
6	Bipolar androgen therapy (BAT): A patient's guide. <i>Prostate</i> , 2022, 82, 753-762.	1.2	6
7	Association of B7H3 expression with racial ancestry, immune cell density, and androgen receptor activation in prostate cancer. <i>Cancer</i> , 2022, 128, 2269-2280.	2.0	16
8	Clinical and pathological features associated with circulating tumor DNA content in real-world patients with metastatic prostate cancer. <i>Prostate</i> , 2022, 82, 867-875.	1.2	10
9	Extreme Responses to a Combination of DNA-Damaging Therapy and Immunotherapy in CDK12-Altered Metastatic Castration-Resistant Prostate Cancer: A Potential Therapeutic Vulnerability. <i>Clinical Genitourinary Cancer</i> , 2022, 20, 183-188.	0.9	3
10	Clinical Efficacy of Bipolar Androgen Therapy in Men with Metastatic Castration-Resistant Prostate Cancer and Combined Tumor-Suppressor Loss. <i>European Urology Open Science</i> , 2022, 41, 112-115.	0.2	4
11	PARP Inhibitor Insensitivity to <i>BRCA1/2</i> Monoallelic Mutations in Microsatellite Instability-High Cancers. <i>JCO Precision Oncology</i> , 2022, , .	1.5	15
12	Genomic Biomarkers and Genome-Wide Loss-of-Heterozygosity Scores in Metastatic Prostate Cancer Following Progression on Androgen-Targeting Therapies. <i>JCO Precision Oncology</i> , 2022, , .	1.5	10
13	Metastasis-directed Therapy Prolongs Efficacy of Systemic Therapy and Improves Clinical Outcomes in Oligoprogressive Castration-resistant Prostate Cancer. <i>European Urology Oncology</i> , 2021, 4, 447-455.	2.6	52
14	A Multicohort Open-label Phase II Trial of Bipolar Androgen Therapy in Men with Metastatic Castration-resistant Prostate Cancer (RESTORE): A Comparison of Post-abiraterone Versus Post-enzalutamide Cohorts. <i>European Urology</i> , 2021, 79, 692-699.	0.9	49
15	Patterns of Recurrence and Modes of Progression After Metastasis-Directed Therapy in Oligometastatic Castration-Sensitive Prostate Cancer. <i>International Journal of Radiation Oncology Biology Physics</i> , 2021, 109, 387-395.	0.4	19
16	<i>CDK12</i> Deficiency and the Immune Microenvironment in Prostate Cancer. <i>Clinical Cancer Research</i> , 2021, 27, 380-382.	3.2	10
17	Tumor Frameshift Mutation Proportion Predicts Response to Immunotherapy in Mismatch Repair-Deficient Prostate Cancer. <i>Oncologist</i> , 2021, 26, e270-e278.	1.9	33
18	Senescence Reprogramming by TIMP1 Deficiency Promotes Prostate Cancer Metastasis. <i>Cancer Cell</i> , 2021, 39, 68-82.e9.	7.7	66

#	ARTICLE	IF	CITATIONS
19	Homologous recombination deficiency (HRD) score in germline BRCA2- versus ATM-altered prostate cancer. <i>Modern Pathology</i> , 2021, 34, 1185-1193.	2.9	61
20	Randomized Phase II Trial of Sipuleucel-T with or without Radium-223 in Men with Bone-metastatic Castration-resistant Prostate Cancer. <i>Clinical Cancer Research</i> , 2021, 27, 1623-1630.	3.2	33
21	Detection of Early Progression with ¹⁸ F-DCFPyL PET/CT in Men with Metastatic Castration-Resistant Prostate Cancer Receiving Bipolar Androgen Therapy. <i>Journal of Nuclear Medicine</i> , 2021, 62, 1270-1273.	2.8	6
22	The Mutational Landscape of Metastatic Castration-sensitive Prostate Cancer: The Spectrum Theory Revisited. <i>European Urology</i> , 2021, 80, 632-640.	0.9	61
23	Prospective, Single-Arm Trial Evaluating Changes in Uptake Patterns on Prostate-Specific Membrane Antigen-Targeted ¹⁸ F-DCFPyL PET/CT in Patients with Castration-Resistant Prostate Cancer Starting Abiraterone or Enzalutamide. <i>Journal of Nuclear Medicine</i> , 2021, 62, 1430-1437.	2.8	24
24	Nivolumab plus ipilimumab, with or without enzalutamide, in AR-expressing metastatic castration-resistant prostate cancer: A phase 2 nonrandomized clinical trial. <i>Prostate</i> , 2021, 81, 326-338.	1.2	35
25	Streamlining Germline Genetic Testing in Prostate Cancer. <i>European Urology Oncology</i> , 2021, 4, 10-11.	2.6	1
26	Development and validation of circulating tumor cell (Epic Sciences) enumeration as a prognostic biomarker in men with metastatic castration-resistant prostate cancer.. <i>Journal of Clinical Oncology</i> , 2021, 39, 157-157.	0.8	0
27	Bipolar androgen therapy sensitizes castration-resistant prostate cancer to subsequent androgen receptor ablative therapy. <i>European Journal of Cancer</i> , 2021, 144, 302-309.	1.3	29
28	NCCN Guidelines Insights: Prostate Cancer, Version 1.2021. <i>Journal of the National Comprehensive Cancer Network: JNCCN</i> , 2021, 19, 134-143.	2.3	299
29	A Randomized Phase II Study of Androgen Deprivation Therapy with or without Palbociclib in RB-positive Metastatic Hormone-Sensitive Prostate Cancer. <i>Clinical Cancer Research</i> , 2021, 27, 3017-3027.	3.2	19
30	Reply to Salma Kaochar, Nicholas Mitsiades Letter to the Editor re: Umang Swami, Pedro Isaacsson Velho, Roberto Nussenzveig, et al. Association of SPOP Mutations with Outcomes in Men with De Novo Metastatic Castration-sensitive Prostate Cancer. <i>Eur Urol</i> 2020, 78:652-6. Can Mutant SPOP Become an Actionable Biomarker for Precision Oncology Management of Prostate Cancer?. <i>European Urology</i> , 2021, 79, e94-e95.	0.9	0
31	Olaparib and rucaparib for the treatment of DNA repair-deficient metastatic castration-resistant prostate cancer. <i>Expert Opinion on Pharmacotherapy</i> , 2021, 22, 1625-1632.	0.9	5
32	TRANSFORMER: A Randomized Phase II Study Comparing Bipolar Androgen Therapy Versus Enzalutamide in Asymptomatic Men With Castration-Resistant Metastatic Prostate Cancer. <i>Journal of Clinical Oncology</i> , 2021, 39, 1371-1382.	0.8	65
33	Association between BRCA2 alterations and intraductal and cribriform histologies in prostate cancer. <i>European Journal of Cancer</i> , 2021, 147, 74-83.	1.3	42
34	Comparison of germline mutations in African American and Caucasian men with metastatic prostate cancer. <i>Prostate</i> , 2021, 81, 433-439.	1.2	29
35	Circulating Tumor Cell Chromosomal Instability and Neuroendocrine Phenotype by Immunomorphology and Poor Outcomes in Men with mCRPC Treated with Abiraterone or Enzalutamide. <i>Clinical Cancer Research</i> , 2021, 27, 4077-4088.	3.2	21
36	AR Splicing Variants and Resistance to AR Targeting Agents. <i>Cancers</i> , 2021, 13, 2563.	1.7	27

#	ARTICLE	IF	CITATIONS
37	Genomic profiles and clinical outcomes in primary versus secondary metastatic hormone-sensitive prostate cancer. <i>Prostate</i> , 2021, 81, 572-579.	1.2	9
38	Mismatch repair-deficient prostate cancer with parenchymal brain metastases treated with immune checkpoint blockade. <i>Journal of Physical Education and Sports Management</i> , 2021, 7, a006094.	0.5	4
39	TGM4: an immunogenic prostate-restricted antigen. , 2021, 9, e001649.		11
40	Differential Activity of PARP Inhibitors in BRCA1- Versus BRCA2-Altered Metastatic Castration-Resistant Prostate Cancer. <i>JCO Precision Oncology</i> , 2021, 5, 1200-1220.	1.5	17
41	Targeting the spectrum of immune checkpoints in prostate cancer. <i>Expert Review of Clinical Pharmacology</i> , 2021, 14, 1253-1266.	1.3	13
42	Abstract 2404: Increased mitochondrial DNA copy number occurs during prostate cancer progression and in cancer precursor lesions across multiple organs. , 2021, , .		0
43	Combined Longitudinal Clinical and Autopsy Phenomic Assessment in Lethal Metastatic Prostate Cancer: Recommendations for Advancing Precision Medicine. <i>European Urology Open Science</i> , 2021, 30, 47-62.	0.2	2
44	Efficacy of systemic therapies in men with metastatic castration resistant prostate cancer harboring germline ATM versus BRCA2 mutations. <i>Prostate</i> , 2021, 81, 1382-1389.	1.2	10
45	Supraphysiologic Testosterone Induces Ferroptosis and Activates Immune Pathways through Nucleophagy in Prostate Cancer. <i>Cancer Research</i> , 2021, 81, 5948-5962.	0.4	30
46	Randomized Phase 2 Trial of Abiraterone Acetate Plus Prednisone, Degarelix, or the Combination in Men with Biochemically Recurrent Prostate Cancer After Radical Prostatectomy. <i>European Urology Open Science</i> , 2021, 34, 70-78.	0.2	3
47	New approaches to targeting the androgen receptor pathway in prostate cancer. <i>Clinical Advances in Hematology and Oncology</i> , 2021, 19, 228-240.	0.3	4
48	Wnt-pathway Activating Mutations Are Associated with Resistance to First-line Abiraterone and Enzalutamide in Castration-resistant Prostate Cancer. <i>European Urology</i> , 2020, 77, 14-21.	0.9	51
49	A pilot trial of pembrolizumab plus prostatic cryotherapy for men with newly diagnosed oligometastatic hormone-sensitive prostate cancer. <i>Prostate Cancer and Prostatic Diseases</i> , 2020, 23, 184-193.	2.0	32
50	Discordant and heterogeneous clinically relevant genomic alterations in circulating tumor cells vs plasma DNA from men with metastatic castration resistant prostate cancer. <i>Genes Chromosomes and Cancer</i> , 2020, 59, 225-239.	1.5	18
51	Mathematical Modeling of Preclinical Alpha-Emitter Radiopharmaceutical Therapy. <i>Cancer Research</i> , 2020, 80, 868-876.	0.4	10
52	Pembrolizumab for Treatment-Refractory Metastatic Castration-Resistant Prostate Cancer: Multicohort, Open-Label Phase II KEYNOTE-199 Study. <i>Journal of Clinical Oncology</i> , 2020, 38, 395-405.	0.8	450
53	Germline BLM mutations and metastatic prostate cancer. <i>Prostate</i> , 2020, 80, 235-237.	1.2	15
54	Practical Considerations and Challenges for Germline Genetic Testing in Patients With Prostate Cancer: Recommendations From the Germline Genetics Working Group of the PCCTC. <i>JCO Oncology Practice</i> , 2020, 16, 811-819.	1.4	35

#	ARTICLE	IF	CITATIONS
55	A MYC and RAS co-activation signature in localized prostate cancer drives bone metastasis and castration resistance. <i>Nature Cancer</i> , 2020, 1, 1082-1096.	5.7	49
56	Role of androgen receptor splice variant-7 (AR-V7) in prostate cancer resistance to 2nd-generation androgen receptor signaling inhibitors. <i>Oncogene</i> , 2020, 39, 6935-6949.	2.6	60
57	Genomic and Clinicopathologic Characterization of ATM-deficient Prostate Cancer. <i>Clinical Cancer Research</i> , 2020, 26, 4869-4881.	3.2	18
58	Neuroendocrine differentiation in usual-type prostatic adenocarcinoma: Molecular characterization and clinical significance. <i>Prostate</i> , 2020, 80, 1012-1023.	1.2	22
59	Reimagining Vaccines for Prostate Cancer: Back to the Future. <i>Clinical Cancer Research</i> , 2020, 26, 5056-5058.	3.2	3
60	BRCA1 Versus BRCA2 and PARP Inhibitor Sensitivity in Prostate Cancer: More Different Than Alike?. <i>Journal of Clinical Oncology</i> , 2020, 38, 3735-3739.	0.8	38
61	PARP Inhibitors in Metastatic Prostate Cancer: Evidence to Date. <i>Cancer Management and Research</i> , 2020, Volume 12, 8105-8114.	0.9	58
62	When and How to Use PARP Inhibitors in Prostate Cancer: A Systematic Review of the Literature with an Update on On-Going Trials. <i>European Urology Oncology</i> , 2020, 3, 594-611.	2.6	63
63	Prospective Multicenter Study of Circulating Tumor Cell AR-V7 and Taxane Versus Hormonal Treatment Outcomes in Metastatic Castration-Resistant Prostate Cancer. <i>JCO Precision Oncology</i> , 2020, 4, 1285-1301.	1.5	42
64	Therapeutic targeting of the DNA damage response in prostate cancer. <i>Current Opinion in Oncology</i> , 2020, 32, 216-222.	1.1	11
65	The MAO inhibitors phenelzine and clorgyline revert enzalutamide resistance in castration resistant prostate cancer. <i>Nature Communications</i> , 2020, 11, 2689.	5.8	41
66	PARP inhibitors in prostate cancer: time to narrow patient selection?. <i>Expert Review of Anticancer Therapy</i> , 2020, 20, 523-526.	1.1	4
67	A phase II randomized trial of Radium-223 dichloride and SABR Versus SABR for oligometastatic prostate cancer (RAVENS). <i>BMC Cancer</i> , 2020, 20, 492.	1.1	16
68	Androgen receptor variant-driven prostate cancer II: advances in laboratory investigations. <i>Prostate Cancer and Prostatic Diseases</i> , 2020, 23, 381-397.	2.0	34
69	Putting the Pieces Together: Completing the Mechanism of Action Jigsaw for Sipuleucel-T. <i>Journal of the National Cancer Institute</i> , 2020, 112, 562-573.	3.0	45
70	Optimizing the role of androgen deprivation therapy in advanced prostate cancer: Challenges beyond the guidelines. <i>Prostate</i> , 2020, 80, 527-544.	1.2	34
71	Impact of DNA damage repair defects on response to radium-223 and overall survival in metastatic castration-resistant prostate cancer. <i>European Journal of Cancer</i> , 2020, 136, 16-24.	1.3	41
72	Association of SPOP Mutations with Outcomes in Men with De Novo Metastatic Castration-sensitive Prostate Cancer. <i>European Urology</i> , 2020, 78, 652-656.	0.9	64

#	ARTICLE	IF	CITATIONS
73	Androgen receptor variant-driven prostate cancer II: advances in clinical investigation. <i>Prostate Cancer and Prostatic Diseases</i> , 2020, 23, 367-380.	2.0	22
74	Does sequencing order of antiandrogens in prostate cancer matter?. <i>Nature Reviews Urology</i> , 2020, 17, 197-198.	1.9	3
75	Emerging treatments for metastatic castration-resistant prostate cancer: Immunotherapy, PARP inhibitors, and PSMA-targeted approaches. <i>Cancer Treatment and Research Communications</i> , 2020, 23, 100164.	0.7	22
76	Extreme responses to immune checkpoint blockade following bipolar androgen therapy and enzalutamide in patients with metastatic castration resistant prostate cancer. <i>Prostate</i> , 2020, 80, 407-411.	1.2	24
77	Outcomes of Observation vs Stereotactic Ablative Radiation for Oligometastatic Prostate Cancer. <i>JAMA Oncology</i> , 2020, 6, 650.	3.4	696
78	CDK12-Altered Prostate Cancer: Clinical Features and Therapeutic Outcomes to Standard Systemic Therapies, Poly (ADP-Ribose) Polymerase Inhibitors, and PD-1 Inhibitors. <i>JCO Precision Oncology</i> , 2020, 4, 370-381.	1.5	138
79	T-Cell Infiltration and Adaptive Treg Resistance in Response to Androgen Deprivation With or Without Vaccination in Localized Prostate Cancer. <i>Clinical Cancer Research</i> , 2020, 26, 3182-3192.	3.2	64
80	TMPRSS2 and COVID-19: Serendipity or Opportunity for Intervention?. <i>Cancer Discovery</i> , 2020, 10, 779-782.	7.7	329
81	Olaparib for DNA repair-deficient prostate cancer – one for all, or all for one?. <i>Nature Reviews Clinical Oncology</i> , 2020, 17, 455-456.	12.5	6
82	KEYNOTE-199 cohorts (C) 4 and 5: Phase II study of pembrolizumab (pembro) plus enzalutamide (enza) for enza-resistant metastatic castration-resistant prostate cancer (mCRPC).. <i>Journal of Clinical Oncology</i> , 2020, 38, 5543-5543.	0.8	17
83	Preclinical studies show using enzalutamide is less effective in docetaxel-pretreated than in docetaxel-naïve prostate cancer cells. <i>Aging</i> , 2020, 12, 17694-17712.	1.4	2
84	Radium-223 plus abiraterone in metastatic castration-resistant prostate cancer: a cautionary tale. <i>Translational Andrology and Urology</i> , 2019, 8, S341-S345.	0.6	7
85	Genomic and clinical characterization of pulmonary-only metastatic prostate cancer: A unique molecular subtype. <i>Prostate</i> , 2019, 79, 1572-1579.	1.2	23
86	Clinical implications of mismatch repair deficiency in prostate cancer. <i>Future Oncology</i> , 2019, 15, 2395-2411.	1.1	29
87	Clinical outcomes associated with pathogenic genomic instability mutations in prostate cancer: a retrospective analysis of US pharmacy and medical claims data. <i>Journal of Medical Economics</i> , 2019, 22, 1080-1087.	1.0	4
88	Reply to L. Dirix, B. De Laere et al, and A. Sharp et al. <i>Journal of Clinical Oncology</i> , 2019, 37, 2184-2186.	0.8	7
89	A pilot study of prostate-specific membrane antigen (PSMA) dynamics in men undergoing treatment for advanced prostate cancer. <i>Prostate</i> , 2019, 79, 1597-1603.	1.2	18
90	Androgen Receptor Modulation Optimized for Response – Splice Variant: A Phase 3, Randomized Trial of Galeterone Versus Enzalutamide in Androgen Receptor Splice Variant-7-expressing Metastatic Castration-resistant Prostate Cancer. <i>European Urology</i> , 2019, 76, 843-851.	0.9	36

#	ARTICLE	IF	CITATIONS
91	<p>Darolutamide For Castration-Resistant Prostate Cancer</p>. OncoTargets and Therapy, 2019, Volume 12, 8769-8777.	1.0	24
92	Phase II Trial of a DNA Vaccine Encoding Prostatic Acid Phosphatase (pTVG-HP [MVI-816]) in Patients With Progressive, Nonmetastatic, Castration-Sensitive Prostate Cancer. Journal of Clinical Oncology, 2019, 37, 3507-3517.	0.8	43
93	Radiation Therapy in the Definitive Management of Oligometastatic Prostate Cancer: The Johns Hopkins Experience. International Journal of Radiation Oncology Biology Physics, 2019, 105, 948-956.	0.4	37
94	PSA Doubling Time and Absolute PSA Predict Metastasis-free Survival in Men With Biochemically Recurrent Prostate Cancer After Radical Prostatectomy. Clinical Genitourinary Cancer, 2019, 17, 470-475.e1.	0.9	26
95	Targeting lineage plasticity in prostate cancer. Lancet Oncology, The, 2019, 20, 1338-1340.	5.1	4
96	A New Molecular Taxonomy to Predict Immune Checkpoint Inhibitor Sensitivity in Prostate Cancer. Oncologist, 2019, 24, 430-432.	1.9	19
97	A phase II randomized placebo-controlled double-blind study of salvage radiation therapy plus placebo versus SRT plus enzalutamide with high-risk PSA-recurrent prostate cancer after radical prostatectomy (SALV-ENZA). BMC Cancer, 2019, 19, 572.	1.1	3
98	Germline Genetic Testing in Advanced Prostate Cancer; Practices and Barriers: Survey Results from the Germline Genetics Working Group of the Prostate Cancer Clinical Trials Consortium. Clinical Genitourinary Cancer, 2019, 17, 275-282.e1.	0.9	42
99	Blocking the PD-1/PD-L1 axis in advanced prostate cancer: are we moving in the right direction?. Annals of Translational Medicine, 2019, 7, S7-S7.	0.7	20
100	Risk of development of visceral metastases subsequent to abiraterone vs placebo: An analysis of mode of radiographic progression in COUâ€AAâ€302. Prostate, 2019, 79, 929-933.	1.2	3
101	Radium-223 in combination with docetaxel in patients with castration-resistant prostate cancer and bone metastases: a phase 1 dose escalation/randomised phase 2a trial. European Journal of Cancer, 2019, 114, 107-116.	1.3	42
102	Prospective Comprehensive Genomic Profiling of Primary and Metastatic Prostate Tumors. JCO Precision Oncology, 2019, 3, 1-23.	1.5	63
103	Prospective Multicenter Validation of Androgen Receptor Splice Variant 7 and Hormone Therapy Resistance in High-Risk Castration-Resistant Prostate Cancer: The PROPHECY Study. Journal of Clinical Oncology, 2019, 37, 1120-1129.	0.8	267
104	Genetic Alterations Detected in Cell-Free DNA Are Associated With Enzalutamide and Abiraterone Resistance in Castration-Resistant Prostate Cancer. JCO Precision Oncology, 2019, 3, 1-14.	1.5	23
105	Differential Response to Olaparib Treatment Among Men with Metastatic Castration-resistant Prostate Cancer Harboring BRCA1 or BRCA2 Versus ATM Mutations. European Urology, 2019, 76, 452-458.	0.9	109
106	A phase I study of the antibody drug conjugate ASG-5ME, an SLC44A4-targeting antibody carrying auristatin E, in metastatic castration-resistant prostate cancer. Investigational New Drugs, 2019, 37, 1052-1060.	1.2	11
107	Circulating tumor cell-based or tissue biopsy-based AR-V7 detection: which provides the greatest clinical utility?. Annals of Translational Medicine, 2019, 7, S354-S354.	0.7	4
108	CDK12 inactivation across solid tumors: an actionable genetic subtype. Oncoscience, 2019, 6, 312-316.	0.9	15

#	ARTICLE	IF	CITATIONS
109	Molecular Characterization and Clinical Outcomes of Primary Gleason Pattern 5 Prostate Cancer After Radical Prostatectomy. <i>JCO Precision Oncology</i> , 2019, 3, 1-13.	1.5	12
110	Pan-Cancer Analysis of <i>CDK12</i> Loss-of-Function Alterations and Their Association with the Focal Tandem-Duplicator Phenotype. <i>Oncologist</i> , 2019, 24, 1526-1533.	1.9	39
111	±-Particle-Emmitter Radiopharmaceutical Therapy: Resistance Is Futile. <i>Cancer Research</i> , 2019, 79, 5479-5481.	0.4	13
112	Genomic Characterization of Prostatic Ductal Adenocarcinoma Identifies a High Prevalence of DNA Repair Gene Mutations. <i>JCO Precision Oncology</i> , 2019, 3, 1-9.	1.5	47
113	Hormonal Therapy or Chemotherapy for Metastatic Prostate Cancer – Playing the Right CARD. <i>New England Journal of Medicine</i> , 2019, 381, 2564-2566.	13.9	5
114	Prevalence of DNA repair gene mutations in localized prostate cancer according to clinical and pathologic features: association of Gleason score and tumor stage. <i>Prostate Cancer and Prostatic Diseases</i> , 2019, 22, 59-65.	2.0	67
115	Stereotactic ablative radiation therapy for oligometastatic prostate cancer delays time-to-next systemic treatment. <i>World Journal of Urology</i> , 2019, 37, 2623-2629.	1.2	21
116	Favorable Response to Pembrolizumab in a Patient With Metastatic Castration-Resistant Prostate Cancer Progressing While Receiving Enzalutamide. <i>Clinical Genitourinary Cancer</i> , 2019, 17, e365-e368.	0.9	2
117	Clinical Features and Therapeutic Outcomes in Men with Advanced Prostate Cancer and DNA Mismatch Repair Gene Mutations. <i>European Urology</i> , 2019, 75, 378-382.	0.9	137
118	Cabozantinib Versus Mitoxantrone-prednisone in Symptomatic Metastatic Castration-resistant Prostate Cancer: A Randomized Phase 3 Trial with a Primary Pain Endpoint. <i>European Urology</i> , 2019, 75, 929-937.	0.9	41
119	PARP inhibition – not all gene mutations are created equal. <i>Nature Reviews Urology</i> , 2019, 16, 4-6.	1.9	17
120	Expression of AR-V7 and ARv567es in Circulating Tumor Cells Correlates with Outcomes to Taxane Therapy in Men with Metastatic Prostate Cancer Treated in TAXYNERGY. <i>Clinical Cancer Research</i> , 2019, 25, 1880-1888.	3.2	92
121	Efficacy of Radium-223 in Bone-metastatic Castration-resistant Prostate Cancer with and Without Homologous Repair Gene Defects. <i>European Urology</i> , 2019, 76, 170-176.	0.9	71
122	Update on Systemic Prostate Cancer Therapies: Management of Metastatic Castration-resistant Prostate Cancer in the Era of Precision Oncology. <i>European Urology</i> , 2019, 75, 88-99.	0.9	333
123	Supraphysiological androgens suppress prostate cancer growth through androgen receptor-mediated DNA damage. <i>Journal of Clinical Investigation</i> , 2019, 129, 4245-4260.	3.9	67
124	Interim results from a phase 2 study of olaparib (without ADT) in men with biochemically-recurrent prostate cancer after prostatectomy, with integrated biomarker analysis.. <i>Journal of Clinical Oncology</i> , 2019, 37, 5045-5045.	0.8	12
125	Pembrolizumab for metastatic castration-resistant prostate cancer (mCRPC) previously treated with docetaxel: Updated analysis of KEYNOTE-199.. <i>Journal of Clinical Oncology</i> , 2019, 37, 216-216.	0.8	8
126	Prostate Cancer, Version 2.2019, NCCN Clinical Practice Guidelines in Oncology. <i>Journal of the National Comprehensive Cancer Network: JNCCN</i> , 2019, 17, 479-505.	2.3	943

#	ARTICLE	IF	CITATIONS
127	Clinical Significance of AR-V567es in Prostate Cancer's Response. <i>Clinical Cancer Research</i> , 2019, 25, 6010-6011.	3.2	1
128	Multiparametric Whole-body MRI with Diffusion-weighted Imaging and ADC Mapping for the Identification of Visceral and Osseous Metastases From Solid Tumors. <i>Academic Radiology</i> , 2018, 25, 1405-1414.	1.3	29
129	PD-1/PD-L1 pathway inhibitors in advanced prostate cancer. <i>Expert Review of Clinical Pharmacology</i> , 2018, 11, 475-486.	1.3	83
130	Germline DNA-repair Gene Mutations and Outcomes in Men with Metastatic Castration-resistant Prostate Cancer Receiving First-line Abiraterone and Enzalutamide. <i>European Urology</i> , 2018, 74, 218-225.	0.9	140
131	Intraductal/ductal histology and lymphovascular invasion are associated with germline DNA repair gene mutations in prostate cancer. <i>Prostate</i> , 2018, 78, 401-407.	1.2	105
132	The evolving landscape of metastatic hormone-sensitive prostate cancer: a critical review of the evidence for adding docetaxel or abiraterone to androgen deprivation. <i>Prostate Cancer and Prostatic Diseases</i> , 2018, 21, 306-318.	2.0	21
133	Sipuleucel-T for the treatment of prostate cancer: novel insights and future directions. <i>Future Oncology</i> , 2018, 14, 907-917.	1.1	112
134	Diagnosing small bowel carcinoid tumor in a patient with oligometastatic prostate cancer imaged with PSMA-Targeted [18 F]DCFPyL PET/CT: Value of the PSMA-RADS-3D Designation. <i>Urology Case Reports</i> , 2018, 17, 22-25.	0.1	7
135	CTC-derived AR-V7 detection as a prognostic and predictive biomarker in advanced prostate cancer. <i>Expert Review of Molecular Diagnostics</i> , 2018, 18, 155-163.	1.5	51
136	p53 status in the primary tumor predicts efficacy of subsequent abiraterone and enzalutamide in castration-resistant prostate cancer. <i>Prostate Cancer and Prostatic Diseases</i> , 2018, 21, 260-268.	2.0	48
137	PARP inhibitors for homologous recombination-deficient prostate cancer. <i>Expert Opinion on Emerging Drugs</i> , 2018, 23, 123-133.	1.0	24
138	Comprehensive Evaluation of Programmed Death-Ligand 1 Expression in Primary and Metastatic Prostate Cancer. <i>American Journal of Pathology</i> , 2018, 188, 1478-1485.	1.9	119
139	A Systematic Review and Framework for the Use of Hormone Therapy with Salvage Radiation Therapy for Recurrent Prostate Cancer. <i>European Urology</i> , 2018, 73, 156-165.	0.9	55
140	Bipolar androgen therapy in men with metastatic castration-resistant prostate cancer after progression on enzalutamide: an open-label, phase 2, multicohort study. <i>Lancet Oncology</i> , The, 2018, 19, 76-86.	5.1	149
141	Muscadine Grape Skin Extract (MPX) in Men with Biochemically Recurrent Prostate Cancer: A Randomized, Multicenter, Placebo-Controlled Clinical Trial. <i>Clinical Cancer Research</i> , 2018, 24, 306-315.	3.2	38
142	Evolving Intersection Between Inherited Cancer Genetics and Therapeutic Clinical Trials in Prostate Cancer: A White Paper From the Germline Genetics Working Group of the Prostate Cancer Clinical Trials Consortium. <i>JCO Precision Oncology</i> , 2018, 2018, 1-14.	1.5	14
143	Circulating Tumor Cell Eradication as an Intermediate Efficacy End Point for Metastatic Castration-Resistant Prostate Cancer: Is There Enough Evidence?. <i>Journal of Clinical Oncology</i> , 2018, 36, 525-527.	0.8	1
144	Targeting Androgen Receptor and DNA Repair in Metastatic Castration-Resistant Prostate Cancer: Results From NCI 9012. <i>Journal of Clinical Oncology</i> , 2018, 36, 991-999.	0.8	169

#	ARTICLE	IF	CITATIONS
145	Targeting ELK1: a wELKome addition to the prostate cancer armamentarium. <i>AME Medical Journal</i> , 2018, 3, 104-104.	0.4	0
146	AR-V7 and treatment selection in advanced prostate cancer: are we there yet?. <i>Precision Cancer Medicine</i> , 2018, 1, 13-13.	1.8	8
147	Ipilimumab plus nivolumab and DNA-repair defects in AR-V7-expressing metastatic prostate cancer. <i>Oncotarget</i> , 2018, 9, 28561-28571.	0.8	129
148	Germline Genetic Testing in Prostate Cancer – Further Enrichment in Variant Histologies?. <i>Oncoscience</i> , 2018, 5, 62-64.	0.9	7
149	Cyclin-Dependent Kinase 12, Immunity, and Prostate Cancer. <i>New England Journal of Medicine</i> , 2018, 379, 1087-1089.	13.9	55
150	Diverse AR-V7 cistromes in castration-resistant prostate cancer are governed by HoxB13. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2018, 115, 6810-6815.	3.3	120
151	Detection of AR-V7 transcript with RNA in situ hybridization in human salivary duct cancer. <i>Oral Oncology</i> , 2018, 84, 134-136.	0.8	4
152	AR Signaling in Human Malignancies: Prostate Cancer and Beyond. <i>Cancers</i> , 2018, 10, 22.	1.7	15
153	Compositional differences in gastrointestinal microbiota in prostate cancer patients treated with androgen axis-targeted therapies. <i>Prostate Cancer and Prostatic Diseases</i> , 2018, 21, 539-548.	2.0	99
154	Microsatellite instability in prostate cancer by PCR or next-generation sequencing. , 2018, 6, 29.		96
155	Abiraterone plus olaparib in prostate cancer: a new form of synthetic lethality?. <i>Lancet Oncology</i> , The, 2018, 19, 860-861.	5.1	7
156	Antigen-Specific CD8 Lytic Phenotype Induced by Sipuleucel-T in Hormone-Sensitive or Castration-Resistant Prostate Cancer and Association with Overall Survival. <i>Clinical Cancer Research</i> , 2018, 24, 4662-4671.	3.2	27
157	Novel Junction-specific and Quantifiable In Situ Detection of AR-V7 and its Clinical Correlates in Metastatic Castration-resistant Prostate Cancer. <i>European Urology</i> , 2018, 73, 727-735.	0.9	55
158	KEYNOTE-199: Pembrolizumab (pembro) for docetaxel-refractory metastatic castration-resistant prostate cancer (mCRPC).. <i>Journal of Clinical Oncology</i> , 2018, 36, 5007-5007.	0.8	72
159	Phase II trial of rucaparib (Without ADT) in patients with metastatic hormone-sensitive prostate cancer harboring germline DNA repair gene mutations (TRIUMPH).. <i>Journal of Clinical Oncology</i> , 2018, 36, TPS5095-TPS5095.	0.8	5
160	Comparison of healthcare resource use and treatment among prostate cancer patients with and without DNA damage repair gene mutations.. <i>Journal of Clinical Oncology</i> , 2018, 36, e17059-e17059.	0.8	0
161	Selective inhibitors of nuclear export: potential therapeutics for AR variant-expressing prostate cancer. <i>Oncotarget</i> , 2018, 9, 35797-35798.	0.8	0
162	Safety and Antitumor Activity of Apalutamide (ARN-509) in Metastatic Castration-Resistant Prostate Cancer with and without Prior Abiraterone Acetate and Prednisone. <i>Clinical Cancer Research</i> , 2017, 23, 3544-3551.	3.2	72

#	ARTICLE	IF	CITATIONS
163	Exploring the optimal sequence of abiraterone and enzalutamide in patients with chemotherapy-resistant prostate cancer: The Kyoto-Baltimore collaboration. <i>International Journal of Urology</i> , 2017, 24, 441-448.	0.5	49
164	Sequencing of Sipuleucel-T and Androgen Deprivation Therapy in Men with Hormone-Sensitive Biochemically Recurrent Prostate Cancer: A Phase II Randomized Trial. <i>Clinical Cancer Research</i> , 2017, 23, 2451-2459.	3.2	58
165	Treatment strategies for DNA repair-deficient prostate cancer. <i>Expert Review of Clinical Pharmacology</i> , 2017, 10, 889-898.	1.3	26
166	Preclinical Study using Malat1 Small Interfering RNA or Androgen Receptor Splicing Variant 7 Degradation Enhancer ASC-J9 [®] to Suppress Enzalutamide-resistant Prostate Cancer Progression. <i>European Urology</i> , 2017, 72, 835-844.	0.9	103
167	Bipolar Androgen Therapy: A Paradoxical Approach for the Treatment of Castration-resistant Prostate Cancer. <i>European Urology</i> , 2017, 72, 323-325.	0.9	14
168	Germline DNA Repair Mutations and Response to Hormonal Therapy in Advanced Prostate Cancer. <i>European Urology</i> , 2017, 72, 43-44.	0.9	12
169	Analytical Validation of Androgen Receptor Splice Variant 7 Detection in a Clinical Laboratory Improvement Amendments (CLIA) Laboratory Setting. <i>Journal of Molecular Diagnostics</i> , 2017, 19, 115-125.	1.2	41
170	BET inhibitors in metastatic prostate cancer: therapeutic implications and rational drug combinations. <i>Expert Opinion on Investigational Drugs</i> , 2017, 26, 1391-1397.	1.9	26
171	Prognostic and predictive biomarkers in prostate cancer: latest evidence and clinical implications. <i>Therapeutic Advances in Medical Oncology</i> , 2017, 9, 565-573.	1.4	58
172	Reply to Julie Steinestel, Christof Bernemann, Andres J. Schrader, and Jochen K. Lennerz's Letter to the Editor re: Emmanuel S. Antonarakis, Changxue Lu, Brandon Luber, et al. Clinical Significance of Androgen Receptor Splice Variant-7 mRNA Detection in Circulating Tumor Cells of Men with Metastatic Castration-resistant Prostate Cancer Treated with First- and Second-line Abiraterone and Enzalutamide. <i>J Clin Oncol</i> 2017;35:2149-56. AR-V7 Testing: What's in it for the Patient?. <i>European Urology</i> , 2017, 72, e170-e171.	0.9	1
173	The impact of statin use on the efficacy of abiraterone acetate in patients with castration-resistant prostate cancer. <i>Prostate</i> , 2017, 77, 1303-1311.	1.2	19
174	MSH2 Loss in Primary Prostate Cancer. <i>Clinical Cancer Research</i> , 2017, 23, 6863-6874.	3.2	122
175	A phase II randomized trial of Observation versus stereotactic ablative Radiation for Oligometastatic prostate Cancer (ORIOLE). <i>BMC Cancer</i> , 2017, 17, 453.	1.1	83
176	Circulating Tumor Cells in Advanced Prostate Cancer: Time to Move from Prognostic to Predictive Ability. <i>European Urology</i> , 2017, 71, 172-173.	0.9	4
177	Comparing Sequencing of Abiraterone and Enzalutamide in Men With Metastatic Castration-Resistant Prostate Cancer: A Retrospective Study. <i>Prostate</i> , 2017, 77, 33-40.	1.2	60
178	Do Patients With AR-V7-Positive Prostate Cancer Benefit from Novel Hormonal Therapies? It All Depends on Definitions. <i>European Urology</i> , 2017, 71, 4-6.	0.9	24
179	Editorial Comment. <i>Journal of Urology</i> , 2017, 197, 142-142.	0.2	0
180	Pharmacodynamic and pharmacokinetic neoadjuvant study of hedgehog pathway inhibitor Sonidegib (LDE-225) in men with high-risk localized prostate cancer undergoing prostatectomy. <i>Oncotarget</i> , 2017, 8, 104182-104192.	0.8	20

#	ARTICLE	IF	CITATIONS
181	Efficacy of Abiraterone and Enzalutamide in Pre- and Postdocetaxel Castration-Resistant Prostate Cancer: A Trial-Level Meta-Analysis. <i>Prostate Cancer</i> , 2017, 2017, 1-8.	0.4	15
182	Altering the Natural History of Oligometastatic Prostate Cancer With Local Therapies: Reality Versus Illusion. <i>Journal of Oncology Practice</i> , 2017, 13, 21-24.	2.5	6
183	Clinical Significance of Androgen Receptor Splice Variant-7 mRNA Detection in Circulating Tumor Cells of Men With Metastatic Castration-Resistant Prostate Cancer Treated With First- and Second-Line Abiraterone and Enzalutamide. <i>Journal of Clinical Oncology</i> , 2017, 35, 2149-2156.	0.8	371
184	Clinical Utility of CLIA-Grade AR-V7 Testing in Patients With Metastatic Castration-Resistant Prostate Cancer. <i>JCO Precision Oncology</i> , 2017, 2017, 1-9.	1.5	42
185	Randomized, Noncomparative, Phase II Trial of Early Switch From Docetaxel to Cabazitaxel or Vice Versa, With Integrated Biomarker Analysis, in Men With Chemotherapy-Naïve, Metastatic, Castration-Resistant Prostate Cancer. <i>Journal of Clinical Oncology</i> , 2017, 35, 3181-3188.	0.8	73
186	Clinical factors associated with AR-V7 detection in ARMOR3-SV, a randomized trial of galeterone (Gal) vs enzalutamide (Enz) in men with AR-V7+ metastatic castration-resistant prostate cancer (mCRPC).. <i>Journal of Clinical Oncology</i> , 2017, 35, 5005-5005.	0.8	23
187	Phase 2 biomarker-driven study of ipilimumab plus nivolumab (Ipi/Nivo) for ARV7-positive metastatic castrate-resistant prostate cancer (mCRPC).. <i>Journal of Clinical Oncology</i> , 2017, 35, 5035-5035.	0.8	19
188	Neoadjuvant randomized trial of degarelix (Deg) ± cyclophosphamide/GVAX (Cy/GVAX) in men with high-risk prostate cancer (PCa) undergoing radical prostatectomy (RP).. <i>Journal of Clinical Oncology</i> , 2017, 35, 5077-5077.	0.8	12
189	Detection fidelity of AR mutations in plasma derived cell-free DNA. <i>Oncotarget</i> , 2017, 8, 15651-15662.	0.8	20
190	Surrogate end points in early prostate cancer clinical states: ready for implementation?. <i>Annals of Translational Medicine</i> , 2017, 5, 502-502.	0.7	3
191	A phase II randomized trial of observation versus stereotactic ablative radiation for oligometastatic prostate cancer (ORIOLE).. <i>Journal of Clinical Oncology</i> , 2017, 35, TPS5094-TPS5094.	0.8	0
192	Prognostic and therapeutic implications of DNA repair gene mutations in advanced prostate cancer. <i>Clinical Advances in Hematology and Oncology</i> , 2017, 15, 785-795.	0.3	19
193	Emerging Molecular Biomarkers in Advanced Prostate Cancer: Translation to the Clinic. <i>American Society of Clinical Oncology Educational Book / ASCO American Society of Clinical Oncology Meeting</i> , 2016, 35, 131-141.	1.8	19
194	Galeterone for the treatment of advanced prostate cancer: the evidence to date. <i>Drug Design, Development and Therapy</i> , 2016, Volume 10, 2289-2297.	2.0	43
195	Medical hospitalizations in prostate cancer survivors. <i>Medical Oncology</i> , 2016, 33, 81.	1.2	2
196	Novel mechanism-based therapeutics for androgen axis blockade in castration-resistant prostate cancer. <i>Current Opinion in Endocrinology, Diabetes and Obesity</i> , 2016, 23, 279-290.	1.2	16
197	Phase 2 Study of the Safety and Antitumor Activity of Apalutamide (ARN-509), a Potent Androgen Receptor Antagonist, in the High-risk Nonmetastatic Castration-resistant Prostate Cancer Cohort. <i>European Urology</i> , 2016, 70, 963-970.	0.9	104
198	PSMA-Based [18F]DCFPyL PET/CT Is Superior to Conventional Imaging for Lesion Detection in Patients with Metastatic Prostate Cancer. <i>Molecular Imaging and Biology</i> , 2016, 18, 411-419.	1.3	202

#	ARTICLE	IF	CITATIONS
199	Analytic Validation of RNA <i>In Situ</i> Hybridization (RISH) for AR and AR-V7 Expression in Human Prostate Cancer. <i>Clinical Cancer Research</i> , 2016, 22, 4651-4663.	3.2	34
200	Lumbosacral Plexus Involvement as the First Site of Metastatic Recurrence in a Patient With CTNNB1-Mutant Prostate Cancer. <i>Clinical Genitourinary Cancer</i> , 2016, 14, e417-e422.	0.9	0
201	Blood Based Detection of Androgen Receptor Splice Variants in Patients with Advanced Prostate Cancer. <i>Journal of Urology</i> , 2016, 196, 1606-1607.	0.2	5
202	Androgen receptor splice variant 7 in castration-resistant prostate cancer: Clinical considerations. <i>International Journal of Urology</i> , 2016, 23, 646-653.	0.5	25
203	Targeting the N-Terminal Domain of the Androgen Receptor: A New Approach for the Treatment of Advanced Prostate Cancer. <i>Oncologist</i> , 2016, 21, 1427-1435.	1.9	60
204	Inherited HSD3B1 polymorphisms and hormonal therapy resistance. <i>Lancet Oncology</i> , The, 2016, 17, 1347-1349.	5.1	1
205	Bipolar Androgen Therapy for Men With Androgen Ablation Naïve Prostate Cancer: Results From the Phase II BATMAN Study. <i>Prostate</i> , 2016, 76, 1218-1226.	1.2	63
206	Cost-Savings Analysis of AR-V7 Testing in Patients With Metastatic Castration-Resistant Prostate Cancer Eligible for Treatment With Abiraterone or Enzalutamide. <i>Prostate</i> , 2016, 76, 1484-1490.	1.2	29
207	Pharmacodynamic study of the oral hedgehog pathway inhibitor, vismodegib, in patients with metastatic castration-resistant prostate cancer. <i>Cancer Chemotherapy and Pharmacology</i> , 2016, 78, 1297-1304.	1.1	23
208	Sequencing Treatment for Castration-Resistant Prostate Cancer. <i>Current Treatment Options in Oncology</i> , 2016, 17, 64.	1.3	29
209	AR aberrations and resistance to abiraterone or enzalutamide. <i>Nature Reviews Urology</i> , 2016, 13, 697-698.	1.9	33
210	Prognostic factors for clinical outcomes in patients with metastatic castration resistant prostate cancer treated with sequential novel androgen receptor-directed therapies. <i>Prostate</i> , 2016, 76, 512-520.	1.2	19
211	Trial Design and Objectives for Castration-Resistant Prostate Cancer: Updated Recommendations From the Prostate Cancer Clinical Trials Working Group 3. <i>Journal of Clinical Oncology</i> , 2016, 34, 1402-1418.	0.8	1,089
212	Novel Insights into Molecular Indicators of Response and Resistance to Modern Androgen-Axis Therapies in Prostate Cancer. <i>Current Urology Reports</i> , 2016, 17, 29.	1.0	22
213	docetaxel-pretreated metastatic castrate-resistant prostate cancer (CRPC)-a prostate cancer clinical trials consortium (PCCTC) study. <i>Investigational New Drugs</i> , 2016, 34, 112-118.	1.2	46
214	Comparison of Prostate-Specific Membrane Antigen-Based ¹⁸ F-DCFBC PET/CT to Conventional Imaging Modalities for Detection of Hormone-Naïve and Castration-Resistant Metastatic Prostate Cancer. <i>Journal of Nuclear Medicine</i> , 2016, 57, 46-53.	2.8	111
215	Co-targeting androgen receptor (AR) and DNA repair: A randomized ETS gene fusion-stratified trial of abiraterone + prednisone (Abi) +/- the PARP1 inhibitor veliparib for metastatic castration-resistant prostate cancer (mCRPC) patients (pts) (NCI9012) – A University of Chicago phase II consortium trial.. <i>Journal of Clinical Oncology</i> , 2016, 34, 5010-5010.	0.8	11
216	AR-V7 and efficacy of abiraterone (Abi) and enzalutamide (Enza) in castration-resistant prostate cancer (CRPC): Expanded analysis of the Johns Hopkins cohort.. <i>Journal of Clinical Oncology</i> , 2016, 34, 5012-5012.	0.8	16

#	ARTICLE	IF	CITATIONS
217	Updated results: A phase I/IIa randomized trial of radium-223 + docetaxel versus docetaxel in patients with castration-resistant prostate cancer and bone metastases.. Journal of Clinical Oncology, 2016, 34, 5075-5075.	0.8	10
218	Patterns of metastatic disease progression after treatment with first-line enzalutamide or abiraterone in castration-resistant prostate cancer (CRPC).. Journal of Clinical Oncology, 2016, 34, e16539-e16539.	0.8	1
219	E2809: Androgen receptor (AR) modulation by bicalutamide (Bic) and MK-2206 (MK) in men with rising PSA at high-risk of progression after local prostate cancer (PC) treatment.. Journal of Clinical Oncology, 2016, 34, 9-9.	0.8	2
220	Emerging Molecular Biomarkers in Advanced Prostate Cancer: Translation to the Clinic. American Society of Clinical Oncology Educational Book / ASCO American Society of Clinical Oncology Meeting, 2016, 36, 131-141.	1.8	16
221	The STAMPEDE trial: paradigm-changing data through innovative trial design. Translational Cancer Research, 2016, 5, S485-S490.	0.4	15
222	Resistance to Novel Antiandrogen Therapies in Metastatic Castration-Resistant Prostate Cancer. Clinical Medicine Insights: Oncology, 2016, 10, 1.	0.6	68
223	Sipuleucel-T (sip-T)â€œinduced proliferative CD8+ T-cell responses to immunizing and secondary antigens.. Journal of Clinical Oncology, 2016, 34, 165-165.	0.8	1
224	Optimal sequencing of enzalutamide and abiraterone in men with metastatic castration-resistant prostate cancer (mCRPC).. Journal of Clinical Oncology, 2016, 34, 308-308.	0.8	0
225	Bipolar androgen therapy (BAT) in men with hormone sensitive (HS) prostate cancer (PC).. Journal of Clinical Oncology, 2016, 34, 236-236.	0.8	0
226	Contemporary treatment patterns and short-term outcomes in men with very high-risk prostate cancer.. Journal of Clinical Oncology, 2016, 34, 103-103.	0.8	0
227	Cost-benefit analysis of AR-V7 testing in patients (Pts) with metastatic castration resistant prostate cancer (mCRPC) eligible for abiraterone (Abi) or enzalutamide (Enza).. Journal of Clinical Oncology, 2016, 34, 283-283.	0.8	0
228	A phase I study of muscadine grape skin extract in men with biochemically recurrent prostate cancer: Safety, tolerability, and dose determination. Prostate, 2015, 75, 1518-1525.	1.2	88
229	Optimal sequencing of docetaxel and abiraterone in men with metastatic castration-resistant prostate cancer. Prostate, 2015, 75, 1814-1820.	1.2	14
230	Androgen Receptor Splice Variant 7 and Efficacy of Taxane Chemotherapy in Patients With Metastatic Castration-Resistant Prostate Cancer. JAMA Oncology, 2015, 1, 582.	3.4	552
231	Does Degree of Androgen Suppression Matter in Hormone-Sensitive Prostate Cancer?. Journal of Clinical Oncology, 2015, 33, 1098-1100.	0.8	10
232	AR splice variant dimerizationâ€œclinical implications. Nature Reviews Urology, 2015, 12, 431-433.	1.9	10
233	The Effect of Therapeutic Anticoagulation on Overall Survival in Men Receiving First-Line Docetaxel Chemotherapy for Metastatic Castration-Resistant Prostate Cancer. Clinical Genitourinary Cancer, 2015, 13, 32-38.	0.9	15
234	Predicting treatment response in castration-resistant prostate cancer: could androgen receptor variant-7 hold the key?. Expert Review of Anticancer Therapy, 2015, 15, 143-145.	1.1	22

#	ARTICLE	IF	CITATIONS
235	A Paracrine Role for IL6 in Prostate Cancer Patients: Lack of Production by Primary or Metastatic Tumor Cells. <i>Cancer Immunology Research</i> , 2015, 3, 1175-1184.	1.6	38
236	Androgen pathway resistance in prostate cancer and therapeutic implications. <i>Expert Opinion on Pharmacotherapy</i> , 2015, 16, 1521-1537.	0.9	50
237	Effect of bipolar androgen therapy for asymptomatic men with castration-resistant prostate cancer: Results from a pilot clinical study. <i>Science Translational Medicine</i> , 2015, 7, 269ra2.	5.8	205
238	Liquid biopsy: Clues on prostate cancer drug resistance. <i>Science Translational Medicine</i> , 2015, 7, 312fs45.	5.8	17
239	Clinical Relevance of Androgen Receptor Splice Variants in Castration-Resistant Prostate Cancer. <i>Current Treatment Options in Oncology</i> , 2015, 16, 57.	1.3	30
240	Abstract CT134: Androgen receptor (AR) mutations in patients (pts) with castration-resistant prostate cancer (CRPC) with and without prior abiraterone acetate (AA) treatment. , 2015, , .		2
241	A phase 1/2 open-label study of safety and antitumor activity of EPI-506, a novel AR N-terminal domain inhibitor, in men with metastatic castration-resistant prostate cancer (mCRPC) with progression after enzalutamide or abiraterone.. <i>Journal of Clinical Oncology</i> , 2015, 33, TPS5072-TPS5072.	0.8	15
242	Clinical Implications of Hedgehog Pathway Signaling in Prostate Cancer. <i>Cancers</i> , 2015, 7, 1983-1993.	1.7	30
243	Resistance to Androgen-Pathway Drugs in Prostate Cancer. <i>New England Journal of Medicine</i> , 2014, 371, 2233-2234.	13.9	24
244	Detection of Circulating Tumor DNA in Early- and Late-Stage Human Malignancies. <i>Science Translational Medicine</i> , 2014, 6, 224ra24.	5.8	3,665
245	The effect of the frequency and duration of PSA measurement on PSA doubling time calculations in men with biochemically recurrent prostate cancer. <i>Prostate Cancer and Prostatic Diseases</i> , 2014, 17, 28-33.	2.0	18
246	Very-high-risk localized prostate cancer: definition and outcomes. <i>Prostate Cancer and Prostatic Diseases</i> , 2014, 17, 57-63.	2.0	91
247	Clinical activity of enzalutamide versus docetaxel in men with castration-resistant prostate cancer progressing after abiraterone. <i>Prostate</i> , 2014, 74, 1278-1285.	1.2	84
248	The Influence of Prior Abiraterone Treatment on the Clinical Activity of Docetaxel in Men with Metastatic Castration-resistant Prostate Cancer. <i>European Urology</i> , 2014, 66, 646-652.	0.9	126
249	Growth factor and signaling pathways and their relevance to prostate cancer therapeutics. <i>Cancer and Metastasis Reviews</i> , 2014, 33, 581-594.	2.7	27
250	Androgen Receptor Splice Variants in the Era of Enzalutamide and Abiraterone. <i>Hormones and Cancer</i> , 2014, 5, 265-273.	4.9	102
251	AR-V7 and Resistance to Enzalutamide and Abiraterone in Prostate Cancer. <i>New England Journal of Medicine</i> , 2014, 371, 1028-1038.	13.9	2,233
252	Clinical activity of enzalutamide in Docetaxel-naïve and Docetaxel-pretreated patients with metastatic castration-resistant prostate cancer. <i>Prostate</i> , 2014, 74, 1560-1568.	1.2	36

#	ARTICLE	IF	CITATIONS
253	Association of pretreatment neutrophil-to-lymphocyte ratio (<sc>NLR</sc>) and overall survival (<sc>OS</sc>) in patients with metastatic castration-resistant prostate cancer (<sc>mCRPC</sc>) treated with first-line docetaxel. <i>BJU International</i> , 2014, 114, E11-E17.	1.3	81
254	Castration-resistant prostate cancer: latest evidence and therapeutic implications. <i>Therapeutic Advances in Medical Oncology</i> , 2014, 6, 167-179.	1.4	67
255	High-Dose Itraconazole As a Noncastrating Therapy for a Patient With Biochemically Recurrent Prostate Cancer. <i>Clinical Genitourinary Cancer</i> , 2014, 12, e51-e53.	0.9	12
256	The effect of prior abiraterone (Abi) use on the activity of enzalutamide (Enza) in men with mCRPC.. <i>Journal of Clinical Oncology</i> , 2014, 32, 18-18.	0.8	28
257	Chemotherapy and its evolving role in the management of advanced prostate cancer. <i>Asian Journal of Andrology</i> , 2014, 16, 334.	0.8	19
258	Enzalutamide in chemo-naïve castration-resistant prostate cancer: effective for most but not for all. <i>Asian Journal of Andrology</i> , 2014, 16, 807.	0.8	5
259	A pilot phase II Study of digoxin in patients with recurrent prostate cancer as evident by a rising PSA. , 2014, 2, 21-32.		12
260	A phase 2 study of KX2-391, an oral inhibitor of Src kinase and tubulin polymerization, in men with bone-metastatic castration-resistant prostate cancer. <i>Cancer Chemotherapy and Pharmacology</i> , 2013, 71, 883-892.	1.1	59
261	Management of Patients with Biochemical Recurrence After Local Therapy for Prostate Cancer. <i>Hematology/Oncology Clinics of North America</i> , 2013, 27, 1205-1219.	0.9	30
262	A non-comparative randomized phase II study of 2 doses of ATN-224, a copper/zinc superoxide dismutase inhibitor, in patients with biochemically recurrent hormone-naïve prostate cancer. <i>Urologic Oncology: Seminars and Original Investigations</i> , 2013, 31, 581-588.	0.8	57
263	Paraneoplastic Palmar Fasciitis and Polyarthrits Syndrome in a Patient With Advanced Prostate Cancer. <i>Clinical Genitourinary Cancer</i> , 2013, 11, e15-e23.	0.9	12
264	Metastasis-free survival is associated with overall survival in men with PSA-recurrent prostate cancer treated with deferred androgen deprivation therapy. <i>Annals of Oncology</i> , 2013, 24, 2881-2886.	0.6	95
265	Molecularly Targeted Agents as Radiosensitizers in Cancer Therapyâ€”Focus on Prostate Cancer. <i>International Journal of Molecular Sciences</i> , 2013, 14, 14800-14832.	1.8	34
266	Repurposing Itraconazole as a Treatment for Advanced Prostate Cancer: A Noncomparative Randomized Phase II Trial in Men With Metastatic Castration-Resistant Prostate Cancer. <i>Oncologist</i> , 2013, 18, 163-173.	1.9	145
267	Phase III Trials With Docetaxel-Based Combinations for Metastatic Castration-Resistant Prostate Cancer: Time to Learn From Past Experiences. <i>Journal of Clinical Oncology</i> , 2013, 31, 1709-1712.	0.8	65
268	Clinical Evaluation of Abiraterone in the Treatment of Metastatic Prostate Cancer. <i>Clinical Medicine Insights Urology</i> , 2013, 7, CMU.S8337.	0.4	4
269	Enzalutamide: an evidence-based review of its use in the treatment of prostate cancer. <i>Core Evidence</i> , 2013, 8, 27.	4.7	22
270	Tumorigenic potential of circulating prostate tumor cells. <i>Oncotarget</i> , 2013, 4, 413-421.	0.8	32

#	ARTICLE	IF	CITATIONS
271	Phase II trial of single-agent ganetespib (STA-9090), a heat shock protein 90 (Hsp90) inhibitor in heavily pretreated patients with metastatic castration-resistant prostate cancer (mCRPC) post docetaxel-based chemotherapy: Results of a Prostate Cancer Clinical Trials Consortium (PCCTC) study.. <i>Journal of Clinical Oncology</i> , 2013, 31, 5085-5085.	0.8	4
272	Association of metastasis-free survival (MFS) with overall survival (OS) in men with PSA-recurrent prostate cancer treated with deferred androgen-deprivation therapy.. <i>Journal of Clinical Oncology</i> , 2013, 31, 109-109.	0.8	2
273	Enzalutamide: The emperor of all anti-androgens. <i>Translational Andrology and Urology</i> , 2013, 2, 119-120.	0.6	8
274	Management of biochemically recurrent prostate cancer after local therapy: evolving standards of care and new directions. <i>Clinical Advances in Hematology and Oncology</i> , 2013, 11, 14-23.	0.3	119
275	Combining immunological and androgen-directed approaches. <i>Current Opinion in Oncology</i> , 2012, 24, 258-265.	1.1	23
276	Current status of immunological approaches for the treatment of prostate cancer. <i>Current Opinion in Urology</i> , 2012, 22, 197-202.	0.9	14
277	Sipuleucel-T for the treatment of metastatic prostate cancer. <i>Human Vaccines and Immunotherapeutics</i> , 2012, 8, 509-519.	1.4	16
278	Immunotherapy for Prostate Cancer Enters Its Golden Age. <i>Clinical Medicine Insights: Oncology</i> , 2012, 6, CMO.S7475.	0.6	6
279	Abiraterone and other novel androgen-directed strategies for the treatment of prostate cancer: a new era of hormonal therapies is born. <i>Therapeutic Advances in Urology</i> , 2012, 4, 167-178.	0.9	56
280	Flagellate erythema secondary to bleomycin. <i>QJM - Monthly Journal of the Association of Physicians</i> , 2012, 105, 901-901.	0.2	2
281	Abiraterone acetate: a hat trick of clinical benefits. <i>Lancet Oncology</i> , The, 2012, 13, 1173-1174.	5.1	2
282	The Experience with Cytotoxic Chemotherapy in Metastatic Castration-Resistant Prostate Cancer. <i>Urologic Clinics of North America</i> , 2012, 39, 573-581.	0.8	4
283	Targeting angiogenesis for the treatment of prostate cancer. <i>Expert Opinion on Therapeutic Targets</i> , 2012, 16, 365-376.	1.5	32
284	Bone-targeting radiopharmaceuticals for the treatment of prostate cancer with bone metastases. <i>Cancer Letters</i> , 2012, 323, 135-146.	3.2	88
285	Surgical Resection of Malignant Melanoma Metastatic to the Pancreas: Case Series and Review of Literature. <i>Journal of Gastrointestinal Cancer</i> , 2012, 43, 431-436.	0.6	21
286	Prostate angiosarcoma: a case report and literature review. <i>Medical Oncology</i> , 2012, 29, 2901-2903.	1.2	8
287	Use of androgen deprivation therapy in prostate cancer: indications and prevalence. <i>Asian Journal of Andrology</i> , 2012, 14, 177-186.	0.8	44
288	Combining active immunotherapy with immune checkpoint blockade for the treatment of advanced prostate cancer. <i>Asian Journal of Andrology</i> , 2012, 14, 520-521.	0.8	10

#	ARTICLE	IF	CITATIONS
289	Lenalidomide modulates IL-8 and anti-prostate antibody levels in men with biochemically recurrent prostate cancer. <i>Prostate</i> , 2012, 72, 487-498.	1.2	13
290	An immunohistochemical signature comprising PTEN, MYC, and Ki67 predicts progression in prostate cancer patients receiving adjuvant docetaxel after prostatectomy. <i>Cancer</i> , 2012, 118, 6063-6071.	2.0	91
291	The natural history of metastatic progression in men with prostate-specific antigen recurrence after radical prostatectomy: long-term follow-up. <i>BJU International</i> , 2012, 109, 32-39.	1.3	221
292	Prostate angiosarcoma: is there any association with previous radiation therapy?. <i>BJU International</i> , 2012, 110, E819-25.	1.3	6
293	The effect of clinical trial participation versus non-participation on overall survival in men receiving first-line docetaxel-containing chemotherapy for metastatic castration-resistant prostate cancer. <i>BJU International</i> , 2012, 110, E575-82.	1.3	28
294	Changes in PSA kinetics predict metastasis-free survival in men with PSA-recurrent prostate cancer treated with nonhormonal agents. <i>Cancer</i> , 2012, 118, 1533-1542.	2.0	47
295	Phase I rapid dose-escalation study of AGS-1C4D4, a human anti-PSCA (prostate stem cell antigen) monoclonal antibody, in patients with castration-resistant prostate cancer: a PCCTC trial. <i>Cancer Chemotherapy and Pharmacology</i> , 2012, 69, 763-771.	1.1	21
296	Treatment of Castration-Resistant Prostate Cancer. , 2012, , 2954-2971.e4.		3
297	Combining active immunotherapy with immune checkpoint blockade for the treatment of advanced prostate cancer. <i>Asian Journal of Andrology</i> , 2012, 14, 655-655.	0.8	1
298	Evolving standards in the treatment of docetaxel-refractory castration-resistant prostate cancer. <i>Prostate Cancer and Prostatic Diseases</i> , 2011, 14, 192-205.	2.0	61
299	Angiotensin system inhibitors and outcome of sunitinib treatment in patients with metastatic renal cell carcinoma: A retrospective examination. <i>European Journal of Cancer</i> , 2011, 47, 1955-1961.	1.3	111
300	Emerging therapeutic approaches in the management of metastatic castration-resistant prostate cancer. <i>Prostate Cancer and Prostatic Diseases</i> , 2011, 14, 206-218.	2.0	25
301	Cabazitaxel: a novel second-line treatment for metastatic castration-resistant prostate cancer. <i>Drug Design, Development and Therapy</i> , 2011, 5, 117.	2.0	111
302	Long-term overall survival and metastasis-free survival for men with prostate-specific antigen-recurrent prostate cancer after prostatectomy: analysis of the Center for Prostate Disease Research National Database. <i>BJU International</i> , 2011, 108, 378-385.	1.3	72
303	The change of PSA doubling time and its association with disease progression in patients with biochemically relapsed prostate cancer treated with intermittent androgen Deprivation. <i>Prostate</i> , 2011, 71, 1608-1615.	1.2	25
304	The unfolding treatment landscape for men with castration-resistant prostate cancer. <i>Clinical Investigation</i> , 2011, 1, 1533-1544.	0.0	2
305	Expanding Treatment Options for Metastatic Prostate Cancer. <i>New England Journal of Medicine</i> , 2011, 364, 2055-2058.	13.9	80
306	Abiraterone acetate for prostate cancer: a new era of hormonal therapies. <i>Asian Journal of Andrology</i> , 2011, 13, 663-664.	0.8	3

#	ARTICLE	IF	CITATIONS
307	Management of metastatic castration-resistant prostate cancer. <i>European Urological Review</i> , 2011, 6, 90-96.	0.0	1
308	Reply to P. Mathew. <i>Journal of Clinical Oncology</i> , 2010, 28, e198-e198.	0.8	0
309	Current status of immunological therapies for prostate cancer. <i>Current Opinion in Urology</i> , 2010, 20, 241-246.	0.9	45
310	Ruthenium-based chemotherapeutics: are they ready for prime time?. <i>Cancer Chemotherapy and Pharmacology</i> , 2010, 66, 1-9.	1.1	421
311	Update: Immunological Strategies for Prostate Cancer. <i>Current Urology Reports</i> , 2010, 11, 202-207.	1.0	30
312	Future Directions in Castrate-Resistant Prostate Cancer Therapy. <i>Clinical Genitourinary Cancer</i> , 2010, 8, 37-46.	0.9	10
313	Lenalidomide in Nonmetastatic Biochemically Relapsed Prostate Cancer: Results of a Phase I/II Double-Blinded, Randomized Study. <i>Clinical Cancer Research</i> , 2010, 16, 5269-5276.	3.2	44
314	Combining low-dose cyclophosphamide with GM-CSF-secreting prostate cancer immunotherapy enhances antitumor immune effects. <i>Expert Opinion on Investigational Drugs</i> , 2010, 19, 311-314.	1.9	11
315	Novel targeted therapeutics for metastatic castration-resistant prostate cancer. <i>Cancer Letters</i> , 2010, 291, 1-13.	3.2	78
316	Is abiraterone acetate well tolerated and effective in the treatment of castration-resistant prostate cancer?. <i>Nature Clinical Practice Oncology</i> , 2009, 6, 12-13.	4.3	13
317	Phase II, Randomized, Placebo-Controlled Trial of Neoadjuvant Celecoxib in Men With Clinically Localized Prostate Cancer: Evaluation of Drug-Specific Biomarkers. <i>Journal of Clinical Oncology</i> , 2009, 27, 4986-4993.	0.8	57
318	Does short-term ADT before and during radiation therapy improve outcomes in locally advanced prostate cancer?. <i>Nature Reviews Urology</i> , 2008, 5, 480-481.	1.4	2
319	Beware of First Impressions. <i>New England Journal of Medicine</i> , 2008, 359, 628-634.	13.9	17
320	Rheumatoid Arthritis Masked by Docetaxel Chemotherapy in a Patient With Ovarian Carcinoma. <i>Journal of Clinical Rheumatology</i> , 2008, 14, 121.	0.5	4
321	Survival in Men With Nonmetastatic Prostate Cancer Treated With Hormone Therapy: A Quantitative Systematic Review. <i>Journal of Clinical Oncology</i> , 2007, 25, 4998-5008.	0.8	38
322	Not What It Seems. <i>American Journal of Medicine</i> , 2007, 120, 408-411.	0.6	0
323	A Cut Above. <i>American Journal of Medicine</i> , 2007, 120, 1031-1033.	0.6	5
324	Pemberton Sign. <i>Mayo Clinic Proceedings</i> , 2007, 82, 859.	1.4	5

#	ARTICLE	IF	CITATIONS
325	Visual Vignette. <i>Endocrine Practice</i> , 2007, 13, 322.	1.1	0
326	Orientation of the stethoscope around the neck: A random phenomenon or an indicator of cerebral lateralisation? Cross-sectional survey. <i>Laterality</i> , 2006, 11, 287-293.	0.5	4
327	An Atypical Complication of Atypical Pneumonia. <i>American Journal of Medicine</i> , 2006, 119, 824-827.	0.6	17
328	Acquired Leukonychia Totalis. <i>New England Journal of Medicine</i> , 2006, 355, e2.	13.9	15
329	Acute psychological stress-induced water intoxication. <i>International Journal of Psychiatry in Clinical Practice</i> , 2005, 9, 142-144.	1.2	2
330	Nausea and vomiting associated with cancer chemotherapy: drug management in theory and in practice. <i>Archives of Disease in Childhood</i> , 2004, 89, 877-880.	1.0	30
331	Prophylaxis of acute chemotherapy-induced nausea and vomiting in children with cancer: What is the evidence?. <i>Pediatric Blood and Cancer</i> , 2004, 43, 651-658.	0.8	22
332	Temperature modulation of DHPLC analysis for detection of coexisting constitutional and mosaic sequence variants in TSC2. <i>Journal of Proteomics</i> , 2002, 51, 161-164.	2.4	15
333	The growing role of rucaparib in contemporary treatment of metastatic prostate cancer: a review of efficacy and guidance for side effect management. <i>Expert Review of Anticancer Therapy</i> , 0, , 1-9.	1.1	1